PT - JOURNAL ARTICLE AU - Christian Hammer AU - Jane Ruppel AU - Julie Hunkapiller AU - Ira Mellman AU - Valerie Quarmby TI - Allelic Variation in <em>HLA-DRB1</em> is Associated with Development of Anti-Drug Antibodies in Cancer Patients Treated with Atezolizumab that are Neutralizing <em>in Vitro</em> AID - 10.1101/2021.04.29.21256008 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.29.21256008 4099 - http://medrxiv.org/content/early/2021/05/03/2021.04.29.21256008.short 4100 - http://medrxiv.org/content/early/2021/05/03/2021.04.29.21256008.full AB - The treatment of diseases with biologic agents can result in the formation of anti-drug antibodies (ADA). The occurrence of ADA were reported for atezolizumab, an anti-PD-L1 monoclonal antibody widely used as immunotherapeutic treatment in cancer patients. Although drivers for ADA formation are unknown, a role for antigen presentation is likely, and variation in human leukocyte antigen (HLA) genes has been shown to be associated with occurrence of ADA for several biologics. Here, we performed an HLA-wide association study in 1,982 patients treated with atezolizumab across 8 clinical trials. On average, 29.8% of patients were ADA positive (N = 591, range of 13.5% -38.4%), and 14.6% of patients were positive for ADA that were neutralizing in vitro (NAb, N = 278, range of 6.4% - 21.9%). We found statistically significant associations between HLA class II alleles and ADA status. The top-associated alleles were HLA-DRB1*01:01 for all ADA (p = 3.4*10−5, odds ratio = 1.96), and HLA-DQA1*01:01 when considering NAb only (p = 2.8 x 10−7, OR = 2.31). Both alleles occur together on a common HLA haplotype, and the ADA association was explained by the NAb subset. In conclusion, our study showed that HLA class II genotype contributes to the risk of developing ADA, and specifically NAb, in patients treated with atezolizumab, but suggests that genetic factors are not sufficient as clinically meaningful predictors.Competing Interest StatementAll authors are employees of Roche/Genentech.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients included in this study signed an optional Research Biosample Repository (RBR) Informed Consent Form (ICF) and provided whole blood samples. By signing the optional RBR ICF, patients provided informed consent for analysis of inherited and non-inherited genetic variation from whole blood samples. Ethics Committees (EC) and Institutional Review Boards (IRB) in each country and each study site for each clinical trial approved the clinical trial protocol, the main study ICF, and the RBR ICF. The EC and IRB for each clinical trial, country, and study site are provided in the Supplementary Data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesHLA association summary statistics are available as Supplementary Results. Qualified researchers may request access to individual patient data used in this study through Roche's data sharing platforms in accordance with the Global Policy on Sharing of Clinical Study Information: http://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm Whole genome sequencing data collected is in this study available under restricted access for biomedical research use only. Applications for access to individual level data should be made to the corresponding authors by email (hammer.christian{at}gene.com). Access to individual level data will require applicants to establish a data sharing agreement with Roche/Genentech to ensure compliance with patient consent and confidentiality obligations.